Search research articles
Contact Us
Filters
Showing results (271-280 of 330) with videos related to
Page
of 33
Sort By:
Research Square
|
May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Breast Cancer Research and Treatment
|
July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
Carey Anders, Allison M Deal, Vandana Abramson, et al.
JAMA Oncology
|
December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
NPJ Precision Oncology
|
February 26, 2026
Tumor genomics in patients younger than 40 years of age with metastatic breast cancer
Kristen D Brantley, Ananya Kodali, Gregory J Kirkner, et al.
Nature Cancer
|
March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results
Rashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Nature Communications
|
December 14, 2023
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
The Lancet. Oncology
|
September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
Nancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M Tung, Mark E Robson, Steffen Ventz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2020
Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
Barbara Pistilli, Angelo Paci, Arlindo R Ferreira, et al.
Nature
|
September 4, 2024
A pathology foundation model for cancer diagnosis and prognosis prediction
Xiyue Wang, Junhan Zhao, Eliana Marostica, et al.
Page
of 33
Search research articles
Search
Showing results (271-280 of 330) with videos related to
Sort By:
Page
of 33
Research Square
|
May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Breast Cancer Research and Treatment
|
July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
Carey Anders, Allison M Deal, Vandana Abramson, et al.
JAMA Oncology
|
December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
NPJ Precision Oncology
|
February 26, 2026
Tumor genomics in patients younger than 40 years of age with metastatic breast cancer
Kristen D Brantley, Ananya Kodali, Gregory J Kirkner, et al.
Nature Cancer
|
March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results
Rashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Nature Communications
|
December 14, 2023
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
The Lancet. Oncology
|
September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
Nancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M Tung, Mark E Robson, Steffen Ventz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2020
Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
Barbara Pistilli, Angelo Paci, Arlindo R Ferreira, et al.
Nature
|
September 4, 2024
A pathology foundation model for cancer diagnosis and prognosis prediction
Xiyue Wang, Junhan Zhao, Eliana Marostica, et al.
Page
of 33